
    
      This is a single-center, interventional clinical trial in which subjects will receive 16 Gy
      of IRay treatment and Lucentis, followed by Lucentis treatment as needed to evaluate the
      efficacy of IRay treatment in patients with PCV as determined by the change in the proportion
      of lesion activity and lesion size at 12 months.
    
  